Literature DB >> 6860076

Plasma phenylalanine, tyrosine, and tryptophan in schizophrenia.

S G Potkin, H E Cannon-Spoor, L E DeLisi, L M Neckers, R J Wyatt.   

Abstract

Plasma phenylalanine, tyrosine, and tryptophan concentrations were measured in chronic schizophrenic patients, normal controls, and heterozygotes for phenylketonuria. Schizophrenic patients' plasma concentrations of these amino acids could not be distinguished from those of normal controls, either when fasting or following oral or intravenous (IV) phenylalanine challenge. No neuroleptic effect was observed. Plasma phenylalanine-tyrosine ratios following IV phenylalanine challenge could easily distinguish heterozygotes from schizophrenic and normal control subjects but could not distinguish schizophrenic subjects from normal control subjects. No overlap between heterozygotes' values and those of the schizophrenic and normal subjects was observed. These studies find no evidence of abnormal phenylalanine metabolism in schizophrenic persons. Phenylalanine challenge did not affect the abstraction or judgment capacities of the subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6860076     DOI: 10.1001/archpsyc.1983.01790060047006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  6 in total

Review 1.  Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide.

Authors:  Abdulla Badawy
Journal:  Psychopharmacology (Berl)       Date:  2013-07-05       Impact factor: 4.530

2.  The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.

Authors:  Abbas F Almulla; Asara Vasupanrajit; Chavit Tunvirachaisakul; Hussein K Al-Hakeim; Marco Solmi; Robert Verkerk; Michael Maes
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 15.992

3.  Tryptophan Metabolism and White Matter Integrity in Schizophrenia.

Authors:  Joshua Chiappelli; Teodor T Postolache; Peter Kochunov; Laura M Rowland; S Andrea Wijtenburg; Dinesh K Shukla; Malle Tagamets; Xiaoming Du; Anya Savransky; Christopher A Lowry; Adem Can; Dietmar Fuchs; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2016-05-04       Impact factor: 7.853

Review 4.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.

Authors:  T Teraishi; Y Ozeki; H Hori; D Sasayama; S Chiba; N Yamamoto; H Tanaka; Y Iijima; J Matsuo; Y Kawamoto; Y Kinoshita; K Hattori; M Ota; M Kajiwara; S Terada; T Higuchi; H Kunugi
Journal:  Transl Psychiatry       Date:  2012-05-22       Impact factor: 6.222

6.  Elevated levels of plasma phenylalanine in schizophrenia: a guanosine triphosphate cyclohydrolase-1 metabolic pathway abnormality?

Authors:  Olaoluwa Okusaga; Olesja Muravitskaja; Dietmar Fuchs; Ayesha Ashraf; Sarah Hinman; Ina Giegling; Annette M Hartmann; Bettina Konte; Marion Friedl; Jason Schiffman; Elliot Hong; Gloria Reeves; Maureen Groer; Robert Dantzer; Dan Rujescu; Teodor T Postolache
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.